REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
3 hedge funds and large institutions have $31K invested in REGENERX BIOPHARMACEUTICALS in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
25% less funds holding
Funds holding: 4 → 3 (-1)
96% less capital invested
Capital invested by funds: $749K → $31K (-$718K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PTC
Philadelphia Trust Company
Philadelphia,
Pennsylvania
|
-$707K |
| 2 |
WJA
Williams Jones & Associates
New York
|
-$1.79K |
RGN Hedge Fund Activity: Q2 2019 in Review
3 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q2 2019, worth a combined $31K — down 96% from $749K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RGN and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Philadelphia Trust Company, exiting entirely with an estimated $707K sold.
- 3 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q2 2019, down from 4 in Q1 2019.
- Funds reported $31K of REGENERX BIOPHARMACEUTICALS stock for Q2 2019, down 96% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q2 2019 and 1 closed out, a net change of -1 holder.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q2 2019 was Philadelphia Trust Company, an estimated $707K sold.
Based on aggregated 13F filings for Q2 2019.